OPEN-LABEL, RANDOMIZED, ASSESSOR-BLINDED, EFFICACY, SAFETY, TOLERABILITY, AND PHARMACOKINETICS STUDY OF SUBCUTANEOUS RISANKIZUMAB WITH AN ADALIMUMAB REFERENCE ARM IN CHILDREN WITH ACTIVE JUVENILE PSORIATIC ARTHRITIS
- Registry ID
- M23-732
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Study type
- INTERVENTIONAL
- Sponsor
- ABBVIE CORPORATION
- Start date
- 2026-04-14
- Last update
- 2024-01-10
Conditions
Related clinical trials
- A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TULISOKIBART IN PARTICIPANTS WITH PSORIATIC ARTHRITIS
- A PHASE 3, PARALLEL-GROUP, RANDOMIZED, DOUBLE-BLIND, 4-ARM, PLACEBOCONTROLLED, MULTICENTER STUDY WITH RISANKIZUMAB AS ACTIVE REFERENCE ARM, TO
INVESTIGATE THE EFFICACY AND SAFETY OF SUBCUTANEOUS SONELOKIMAB IN MALE AND
FEMALE PARTICIPANTS AGED 18 YEARS AND OVER WITH ACTIVE PSORIATIC ARTHRITIS AND
PREVIOUS INADEQUATE RESPONSE OR INTOLERANCE TO TUMOR NECROSIS FACTOR-¿
INHIBITORS
- OPEN-LABEL, SINGLE-ARM TRIAL TO EVALUATE THE PHARMACOKINETICS AND SAFETY OF BIMEKIZUMAB IN PEDIATRIC STUDY PARTICIPANTS FROM 2 TO LESS THAN 18 YEARS OF AGE WITH ACTIVE JUVENILE IDIOPATHIC ARTHRITIS SUBTYPES ENTHESITIS-RELATED ARTHRITIS (INCLUDING JUVENILE-ONSET ANKYLOSING SPONDYLITIS) AND JUVENILE PSORIATIC ARTHRITIS
- A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER PHASE 2B/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF IZOKIBEP IN SUBJECTS WITH ACTIVE PSORIATIC ARTHRITIS
- A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO DEMONSTRATE THE EFFICACY AND SAFETY OF TILDRAKIZUMAB IN ANTI-TNF EXPERIENCED SUBJECTS WITH ACTIVE PSORIATIC ARTHRITIS I (INSPIRE 1)
- A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DEUCRAVACITINIB IN PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS (PSA) WHO ARE NAÏVE TO BIOLOGIC DISEASE MODIFYING ANTIRHEUMATIC DRUGS OR HAD PREVIOUSLY RECEIVED TNF¿ INHIBITOR TREATMENT
View on source registry